Guidelines for the use of 18F-FDG in infection and inflammation: a new step in cooperation between the EANM and SNMMI

Buscombe, J. R.

doi:10.1007/s00259-013-2380-4

Cited by 7 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior to FDG-injection, patients fasted for at least six hours without glucose containing infusions. Patients with diabetes were managed according to EANM guidelines [17]. A weightadjusted dose of 4 MBq/kg FDG (maximum 400 MBq) was administered and after one hour, a low-dose CT without contrast-enhancement was obtained from the base of the skull to the proximal femora for anatomic correlation and attenuation-correction of PET-images.…”

Section: Fdg-pet/ctmentioning

confidence: 99%

Clinical value of FDG-PET/CT in bacteremia of unknown origin with catalase-negative gram-positive cocci or Staphylococcus aureus

Brøndserud

Pedersen

Rosenvinge

et al. 2019

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Bacteremia is associated with high mortality, especially when the site of infection is unknown. While conventional imaging usually focuses on specific body parts, FDG-PET/CT visualizes hypermetabolic foci throughout the body. Purpose: To investigate the ability of FDG/PET-CT to detect site of infection and its clinical impact in bacteremia of unknown origin with catalase-negative Gram-positive cocci (excluding pneumococci and enterococci) or Staphylococcus aureus (BUOCSA). Methods: We retrospectively identified 157 patients with 165 episodes of BUOCSA, who subsequently underwent FDG-PET/CT. Data were collected from medical records. Decision regarding important sites of infection in patients with bacteremia was based on the entire patient course and served as reference diagnosis for comparison with FDG-PET/CT findings. FDG-PET/CT was considered to have high clinical impact if it correctly revealed site(s) of infection in areas not assessed by other imaging modalities or if other imaging modalities were negative/equivocal in these areas, or if it established a new clinically relevant diagnosis, and/or led to change in antimicrobial treatment. Results: FDG-PET/CT detected sites of infection in 56.4% of cases and had high clinical impact in 47.3%. It was the first imaging modality to identify sites of infection in 41.1% bacteremia cases, led to change of antimicrobial therapy in 14.7%, and established a new diagnosis unrelated to bacteremia in 9.8%. Detection rate and clinical impact weren't significantly influenced by duration of antimicrobial treatment preceding FDG-PET/CT, days from suspicion of bacteremia to FDG-PET/CT-scan, type of bacteremia, or cancer. Conclusion: FDG-PET/CT appears clinically useful in BUOCSA. Prospective studies are warranted for confirmation.

show abstract

Section: Fdg-pet/ctmentioning

confidence: 99%

Clinical value of FDG-PET/CT in bacteremia of unknown origin with catalase-negative gram-positive cocci or Staphylococcus aureus

Brøndserud

Pedersen

Rosenvinge

et al. 2019

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…Due to 18 F-FDG having similar biochemical properties to glucose, it can enter cells through the glucose transporter on the cell membrane, where it is phosphorylated to 6-PO 4 - 18 F-FDG by hexokinase, and it remains in the cell. 18 F-FDG PET/CT imaging can reflect glucose metabolism of tissues and organs in the body [ 15 , 16 ]. At present, 18 F-FDG PET imaging has been used to study the glucose metabolism of organs such as the liver, fat, skeletal muscle, and myocardium [ 17 – 19 ], and the results show that this approach allows for the effective evaluation of glucose uptake by these organs.…”

Section: Introductionmentioning

confidence: 99%

The difference between steroid diabetes mellitus and type 2 diabetes mellitus: a whole-body 18F-FDG PET/CT study

et al. 2020

View full text Add to dashboard Cite

Aims Steroid diabetes mellitus (SDM) is a metabolic syndrome caused by an increase in glucocorticoids, and its pathogenesis is unclear. 18F-FDG PET/CT can reflect the glucose metabolism of tissues and organs under living conditions. Here, PET/CT imaging of SDM and type 2 diabetes mellitus (T2DM) rats was used to visualize changes in glucose metabolism in the main glucose metabolizing organs and investigate the pathogenesis of SDM. Methods SDM and T2DM rat models were established. During this time, PET/CT imaging was used to measure the %ID/g value of skeletal muscle and liver to evaluate glucose uptake. The pancreatic, skeletal muscle and liver were analyzed by immunohistochemistry. Results SDM rats showed increased fasting blood glucose and insulin levels, hyperplasia of islet α and β cells, increased FDG uptake in skeletal muscle accompanied by an up-regulation of PI3Kp85α, IRS-1, and GLUT4, no significant changes in liver uptake, and that glycogen storage in the liver and skeletal muscle increased. T2DM rats showed atrophy of pancreatic islet β cells and decreased insulin levels, significantly reduced FDG uptake and glycogen storage in skeletal muscle and liver. Conclusions The pathogenesis of SDM is different from that of T2DM. The increased glucose metabolism of skeletal muscle may be related to the increased compensatory secretion of insulin. Glucocorticoids promote the proliferation of islet α cells and cause an increase in gluconeogenesis in the liver, which may cause increased blood glucose.

show abstract

“…Due to 18 F-FDG having similar biochemical properties to glucose, it can enter cells through the glucose transporter on the cell membrane, where it is phosphorylated to 6-PO 4 -18 F-FDG by hexokinase, and it remains in the cell. 18 F-FDG PET/CT imaging can reflect glucose metabolism of tissues and organs in the body (21,22). At present, 18 F-FDG PET imaging has been used to study the glucose metabolism of organs such as the liver, fat, skeletal muscle, and myocardium (23)(24)(25), and the results show that this approach allows for the effective evaluation of glucose uptake by these organs.…”

Section: Introductionmentioning

confidence: 99%

The difference between steroid diabetes mellitus and type 2 diabetes mellitus: A whole-body 18F-FDG PET/CT study

Zhao

Zhou

Pan

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Steroid diabetes mellitus (SDM) is a metabolic syndrome caused by an increase in glucocorticoids, and its pathogenesis is unclear. 18F-FDG PET/CT can reflect the glucose metabolism of tissues and organs under living conditions, and plays an important role in diabetes research. Here, PET/CT imaging of SDM and type 2 diabetes mellitus (T2DM) rats was used to observe the changes of glucose metabolism in major glucose metabolism organs and immunohistochemical analysis to explore the possible pathogenesis of SDM. Results The SDM rat model was successfully established, which showed increased FBG and insulin levels; 18F-FDG PET/CT imaging showed increased FDG uptake in skeletal muscle, but no significant increase in liver uptake (15d);Immunohistochemistry showed that islet α-cell and β-cell proliferation, GLUT-4 and IRS-1, PI3Kp85α expression in skeletal muscle increased, and glycogen storage in liver and skeletal muscle increased.T2DM rats showed atrophy of pancreatic islet β cells and decreased insulin levels; Significantly reduced FDG uptake and glycogen storage in skeletal muscle and liver; IRS-1 expression in skeletal muscle decreased, and GLUT-4 and PI3Kp85α did not change significantly. Conclusion The pathogenesis of SDM is different from that of T2DM. The increased glucose metabolism of skeletal muscle may be related to the increased compensatory secretion of insulin; glucocorticoids promote the proliferation of islet α cells and cause the increase of gluconeogenesis in the liver may be the cause of its increased blood glucose.

show abstract

Guidelines for the use of 18F-FDG in infection and inflammation: a new step in cooperation between the EANM and SNMMI

Cited by 7 publications

References 10 publications

Clinical value of FDG-PET/CT in bacteremia of unknown origin with catalase-negative gram-positive cocci or Staphylococcus aureus

Clinical value of FDG-PET/CT in bacteremia of unknown origin with catalase-negative gram-positive cocci or Staphylococcus aureus

The difference between steroid diabetes mellitus and type 2 diabetes mellitus: a whole-body 18F-FDG PET/CT study

The difference between steroid diabetes mellitus and type 2 diabetes mellitus: A whole-body 18F-FDG PET/CT study

Contact Info

Product

Resources

About